| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6087770 | Clinical Immunology | 2012 | 18 Pages |
Abstract
⺠JIA pathogenesis involves dysregulation of both adaptive and innate immunity. ⺠Drugs interacting with TNFα and IL-1β are increasingly being used in JIA treatment. ⺠An evidence-based multidisciplinary consensus was created. ⺠Evidence and consensus-based guidelines may be a useful tool to standardize JIA care.
Keywords
MTXCouncil for International Organizations of Medical SciencesEuropean Medical AgencyCTLA-4TNFFDAEULAREBMCIOMSTPMTJDMSoJIAMAXDMARDsJIANGTCAPSEMAIgGNSAIDACRScTJuvenile idiopathic arthritiscytotoxic T-lymphocyte antigen 4ConsensusAppraisal of Guidelines for Research and EvaluationILARimmunoglobulin GinterleukinMASMaximumdisease modifying anti-rheumatic drugscluster of differentiationJuvenile dermatomyositisTreatmentGuidelineNominal group techniqueFood and Drug AdministrationGPSMacrophage activation syndromeCryopyrin-associated periodic syndromesAdverse eventstumor necrosis factorSLEEuropean League Against RheumatismMethotrexateAGREEbodyweightGeneral practitionersEvidence based medicineStem cell transplantationAmerican College of RheumatologyChildren and adolescentsGlucocorticoids
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Gregor Dueckers, Nihal Guellac, Martin Arbogast, Guenther Dannecker, Ivan Foeldvari, Michael Frosch, Gerd Ganser, Arnd Heiligenhaus, Gerd Horneff, Arnold Illhardt, Ina Kopp, Ruediger Krauspe, Barbara Markus, Hartmut Michels, Matthias Schneider,